Bref: Sequana Medical Announces FDA Approval To Expand Patient Enrolment In North American Pivotal Alfapump Study

Sequana Medical NV

04/10/2021 06:18

Oct 4 (Reuters) - SEQUANA MEDICAL NV  SEQUA.BR :   
    * ANNOUNCES FDA APPROVAL TO EXPAND PATIENT ENROLMENT IN
NORTH
AMERICAN PIVOTAL ALFAPUMP® STUDY (POSEIDON)
    * PRIMARY ENDPOINT READ-OUT DUE IN Q4 2022
    * COMPLETION OF PATIENT ENROLMENT EXPECTED BEFORE END OF
YEAR
    * 59 PATIENTS ALREADY RECRUITED IN PIVOTAL COHORT

  
Further company coverage:  SEQUA.BR  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))